Skip to main content

Advertisement

SpringerLink
Log in

Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia: To Whom, When, and How

  • Leukemia (A Aguayo, Section Editor)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Allogeneic hematopoietic stem cell transplant (HSCT) is an established treatment modality with curative potential for acute myeloid leukemia (AML). There has been a significant rise in the number of HSCT procedures performed over the past decade due in part to improved supportive care and innovative techniques such as reduced-intensity conditioning. Expanding alternative donor options such as umbilical cord blood and haploidentical HSCT, taken together with improved outcomes of matched unrelated donors, has resulted in a suitable donor for most patients with an HSCT indication. Recent advances in molecular diagnostics that incorporate genetic mutational analysis into existing cytogenetic-based models should improve selection of patients at high risk of relapse most likely to benefit from HSCT. Improvements in minimal residual disease monitoring hold promise for adding prognostic information, and informing the clinician of impending relapse. The choice of the conditioning regimen involves weighing a patient's unique toxicity and relapse risks. Despite improvements, relapse remains the primary source of treatment failure after HSCT for treatment of AML. The introduction of novel therapies into the clinic, together with improved patient selection, offers hope for decreasing relapse and improving outcomes for AML patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Pasquini MC, Wang Z. Current uses and outcomes of hematopoietic stem cell transplantation 2012. Summary slides. CIBMTR. 2012. Available via http://www.cibmtr.org/referencecenter/slidesreports/summaryslides/pages/index.aspx.

  2. • Stone RM. Acute myeloid leukemia in first remission: to choose transplantation or not? J Clin Oncol. 2013;31(10):1262–6. This is an excellent review of the evidence for and against HSCT in CR1 AML. Relapse risk is discussed in the context of cytogenetic and genetic mutation, with a suggested patient selection algorithm.

    Article  PubMed  Google Scholar 

  3. Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363(22):2091–101.

    Article  PubMed  CAS  Google Scholar 

  4. Tallman MS, Dewald GW, Gandham S, Logan BR, Keating A, Lazarus HM, et al. Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission. Blood. 2007;110(1):409–17.

    Article  PubMed  CAS  Google Scholar 

  5. Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009;301(22):2349–61.

    Article  PubMed  CAS  Google Scholar 

  6. Burnett AK, Goldstone A, Hills RK, Milligan D, Prentice A, Yin J, et al. Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission. J Clin Oncol. 2013;31(10):1293–301.

    Article  PubMed  Google Scholar 

  7. • Cornelissen JJ, Breems D, van Putten WL, Gratwohl AA, Passweg JR, Pabst T, et al. Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories. J Clin Oncol. 2012;30(17):2140–6. This is a large European registry analysis outlining the very poor prognosis of AML with monosomal karyotype. Data supporting a modest benefit for HSCT are given.

    Article  PubMed  Google Scholar 

  8. Kayser S, Zucknick M, Dohner K, Krauter J, Kohne CH, Horst HA, et al. Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies. Blood. 2012;119(2):551–8.

    Article  PubMed  CAS  Google Scholar 

  9. Mohr B, Schetelig J, Schafer-Eckart K, Schmitz N, Hanel M, Rosler W, et al. Impact of allogeneic haematopoietic stem cell transplantation in patients with abnl(17p) acute myeloid leukaemia. Br J Haematol. 2013;161(2):237–44.

    Article  PubMed  Google Scholar 

  10. • Middeke JM, Beelen D, Stadler M, Gohring G, Schlegelberger B, Baurmann H, et al. Outcome of high-risk acute myeloid leukemia after allogeneic hematopoietic cell transplantation: negative impact of abnl(17p) and −5/5q. Blood. 2012;120(12):2521–8. Similarly to other oncologic diagnoses, abnl(17p) confers one of the worst cytogenetic risks known. In light of these data, such patients are in need of novel therapeutic strategies.

    Article  PubMed  CAS  Google Scholar 

  11. • Armand P, Kim HT, Zhang MJ, Perez WS, Dal Cin PS, Klumpp TR, et al. Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study. Biol Blood Marrow Transplant. 2012;18(2):280–8. This large registry review by the CIBMTR aims to validate existing cytogenetic risk classification and proposes a new HSCT-specific cytogenic risk model.

    Article  PubMed  Google Scholar 

  12. Paschka P, Marcucci G, Ruppert AS, Mrozek K, Chen H, Kittles RA, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B study. J Clin Oncol. 2006;24(24):3904–11.

    Article  PubMed  CAS  Google Scholar 

  13. Liu H, Stock W, Bishop MR. Expanded indications for allogeneic stem cell transplantation in patients with myeloid malignancies. Curr Opin Hematol. 2013;20(2):115–22.

    Article  PubMed  CAS  Google Scholar 

  14. • Ofran Y, Rowe JM. Genetic profiling in acute myeloid leukaemia ─ where are we and what is its role in patient management. Br J Haematol. 2013;160(3):303–20. This excellent review is recommended for the reader seeking a more in depth introduction to the prognostic and predictive roles of genetic profiling in AML.

    Article  PubMed  CAS  Google Scholar 

  15. Rollig C, Bornhauser M, Thiede C, Taube F, Kramer M, Mohr B, et al. Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system. J Clin Oncol. 2011;29(20):2758–65.

    Article  PubMed  Google Scholar 

  16. Brunet S, Labopin M, Esteve J, Cornelissen J, Socie G, Iori AP, et al. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. J Clin Oncol. 2012;30(7):735–41.

    Article  PubMed  Google Scholar 

  17. Sengsayadeth SM, Jagasia M, Engelhardt BG, Kassim A, Strickland SA, Goodman S, et al. Allo-SCT for high-risk AML-CR1 in the molecular era: impact of FLT3/ITD outweighs the conventional markers. Bone Marrow Transplant. 2012;47(12):1535–7.

    Article  PubMed  CAS  Google Scholar 

  18. Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358(18):1909–18.

    Article  PubMed  CAS  Google Scholar 

  19. • Brunet S, Martino R, Sierra J. Hematopoietic transplantation for acute myeloid leukemia with internal tandem duplication of FLT3 gene (FLT3/ITD). Curr Opin Oncol. 2013;25(2):195–204. This is an in-depth focused review on the current role of HSCT in treating FLT3-ITD mutation AML.

    Article  PubMed  CAS  Google Scholar 

  20. Marcucci G, Maharry K, Radmacher MD, Mrozek K, Vukosavljevic T, Paschka P, et al. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B study. J Clin Oncol. 2008;26(31):5078–87.

    Article  PubMed  CAS  Google Scholar 

  21. Pratcorona M, Brunet S, Nomdedeu J, Ribera JM, Tormo M, Duarte R, et al. Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. Blood. 2013;121(14):2734–8.

    Article  PubMed  CAS  Google Scholar 

  22. • Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366(12):1079–89. Using a panel of 18 genes, the investigators identified somatic alterations in 97% of AML patients. This study demonstrates co-occurrence of mutations and their effect on outcomes in various cytogenetic risk groups. The role of IDH1/IDH2 mutations in the context of NPM1 is reported as are the response of patients with DNMT3A to high-dose daunorubicin.

    Article  PubMed  CAS  Google Scholar 

  23. Walter RB, Gooley TA, Wood BL, Milano F, Fang M, Sorror ML, et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol. 2011;29(9):1190–7.

    Article  PubMed  Google Scholar 

  24. Chen Y, Cortes J, Estrov Z, Faderl S, Qiao W, Abruzzo L, et al. Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation. J Clin Oncol. 2011;29(18):2507–13.

    Article  PubMed  Google Scholar 

  25. Oran B, Popat U, Rondon G, Ravandi F, Garcia-Manero G, Abruzzo L, et al. Significance of persistent cytogenetic abnormalities on myeloablative allogeneic stem cell transplantation in first complete remission. Biol Blood Marrow Transplant. 2013;19(2):214–20.

    Article  PubMed  Google Scholar 

  26. Rosenow F, Berkemeier A, Krug U, Muller-Tidow C, Gerss J, Silling G, et al. CD+ lineage specific donor cell chimerism for the diagnosis and treatment of impending relapse of AML or myelodysplastic syndrome after allo-SCT. Bone Marrow Transplant. 2013. doi:10.1038/bmt.2013.2.

    PubMed  Google Scholar 

  27. Polak J, Hajkova H, Haskovec C, Cechova H, Marinov I, Mikulenkova D, et al. Quantitative monitoring of WT1 expression in peripheral blood before and after allogeneic stem cell transplantation for acute myeloid leukemia - a useful tool for early detection of minimal residual disease. Neoplasma. 2013;60(1):74–82.

    Article  PubMed  CAS  Google Scholar 

  28. Gupta V, Tallman MS, He W, Logan BR, Copelan E, Gale RP, et al. Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis. Blood. 2010;116(11):1839–48.

    Article  PubMed  CAS  Google Scholar 

  29. Imahashi N, Suzuki R, Fukuda T, Kakihana K, Kanamori H, Eto T, et al. Allogeneic hematopoietic stem cell transplantation for intermediate cytogenetic risk AML in first CR. Bone Marrow Transplant. 2013;48(1):56–62.

    Article  PubMed  CAS  Google Scholar 

  30. • Saber W, Opie S, Rizzo JD, Zhang MJ, Horowitz MM, Schriber J. Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia. Blood. 2012;119(17):3908–16. This is a very large registry analysis showing equivalent outcomes between matched unrelated donor HSCT and matched related donor HSCT in AML.

    Article  PubMed  CAS  Google Scholar 

  31. Brunstein CG, Fuchs EJ, Carter SL, Karanes C, Costa LJ, Wu J, et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood. 2011;118(2):282–8.

    Article  PubMed  CAS  Google Scholar 

  32. Brunstein CG, Eapen M, Ahn KW, Appelbaum FR, Ballen KK, Champlin RE, et al. Reduced-intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes. Blood. 2012;119(23):5591–8.

    Article  PubMed  CAS  Google Scholar 

  33. Chen YB, Aldridge J, Kim HT, Ballen KK, Cutler C, Kao G, et al. Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor grafts. Biol Blood Marrow Transplant. 2012;18(5):805–12.

    Article  PubMed  Google Scholar 

  34. • Huang XJ, Zhu HH, Chang YJ, Xu LP, Liu DH, Zhang XH, et al. The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission. Blood. 2012;119(23):5584–90. For patients with AML without suitable donors, haploidentical donor HSCT provides a survival advantage compared with chemotherapy alone.

    Article  PubMed  CAS  Google Scholar 

  35. Szer J. The prevalent predicament of relapsed acute myeloid leukemia. Hematol Am Soc Hematol Educ Program. 2012;2012:43–8.

    Google Scholar 

  36. Sorror ML, Sandmaier BM, Storer BE, Franke GN, Laport GG, Chauncey TR, et al. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA. 2011;306(17):1874–83.

    Article  PubMed  CAS  Google Scholar 

  37. Alatrash G, de Lima M, Hamerschlak N, Pelosini M, Wang X, Xiao L, et al. Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life. Biol Blood Marrow Transplant. 2011;17(10):1490–6.

    Article  PubMed  CAS  Google Scholar 

  38. Aoudjhane M, Labopin M, Gorin NC, Shimoni A, Ruutu T, Kolb HJ, et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia. 2005;19(12):2304–12.

    Article  PubMed  CAS  Google Scholar 

  39. Ringden O, Labopin M, Ehninger G, Niederwieser D, Olsson R, Basara N, et al. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J Clin Oncol. 2009;27(27):4570–7.

    Article  PubMed  Google Scholar 

  40. Luger SM, Ringden O, Zhang MJ, Perez WS, Bishop MR, Bornhauser M, et al. Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplant. 2012;47(2):203–11.

    Article  PubMed  CAS  Google Scholar 

  41. Bornhauser M, Kienast J, Trenschel R, Burchert A, Hegenbart U, Stadler M, et al. Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. Lancet Oncol. 2012;13(10):1035–44.

    Article  PubMed  Google Scholar 

  42. Chen YB, Coughlin E, Kennedy KF, Alyea EP, Armand P, Attar EC, et al. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia. Biol Blood Marrow Transplant. 2013;19(6):981–7.

    Article  PubMed  CAS  Google Scholar 

  43. Nagler A, Labopin M, Shimoni A, Niederwieser D, Mufti GJ, Zander AR, et al. Mobilized peripheral blood stem cells compared with bone marrow as the stem cell source for unrelated donor allogeneic transplantation with reduced-intensity conditioning in patients with acute myeloid leukemia in complete remission: an analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2012;18(9):1422–9.

    Article  PubMed  Google Scholar 

  44. Weisdorf D, Zhang MJ, Arora M, Horowitz MM, Rizzo JD, Eapen M. Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning. Biol Blood Marrow Transplant. 2012;18(11):1727–33.

    Article  PubMed  Google Scholar 

  45. Bredeson C, Le-Rademacher J, Zhu X, Burkart J, Kato K, Armstrong E, et al. Improved survival with intravenous busulfan (IV BU) compared to total body irradiation (TBI)-based myeloablative conditioning regimens: a CIBMTR prospective study. Biol Blood Marrow Transplant. 2013;19(2 Suppl):S110–1.

    Article  Google Scholar 

  46. Rozman C, Carreras E, Qian C, Gale RP, Bortin MM, Rowlings PA, et al. Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia. Bone Marrow Transplant. 1996;17(1):75–80.

    PubMed  CAS  Google Scholar 

  47. Liu H, Zhai X, Song Z, Sun J, Xiao Y, Nie D, et al. Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study. J Hematol Oncol. 2013;6:15.

    Article  PubMed  CAS  Google Scholar 

  48. Chevallier P, Labopin M, Milpied N, Cornelissen JJ, Blaise D, Petersen E, et al. Impact of cytogenetics risk on outcome after reduced intensity conditioning allo-SCT from an HLA-identical sibling for patients with AML in first CR: a report from the acute leukemia working party of EBMT. Bone Marrow Transplant. 2012;47(11):1442–7.

    Article  PubMed  CAS  Google Scholar 

  49. Biggs JC, Horowitz MM, Gale RP, Ash RC, Atkinson K, Helbig W, et al. Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. Blood. 1992;80(4):1090–3.

    PubMed  CAS  Google Scholar 

  50. Armistead PM, de Lima M, Pierce S, Qiao W, Wang X, Thall PF, et al. Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia. Biol Blood Marrow Transplant. 2009;15(11):1431–8.

    Article  PubMed  Google Scholar 

  51. Song KW, Lipton J. Is it appropriate to offer allogeneic hematopoietic stem cell transplantation to patients with primary refractory acute myeloid leukemia? Bone Marrow Transplant. 2005;36(3):183–91.

    Article  PubMed  CAS  Google Scholar 

  52. Blennow O, Remberger M, Klingspor L, Omazic B, Fransson K, Ljungman P, et al. Randomized PCR-based therapy and risk factors for invasive fungal infection following reduced-intensity conditioning and hematopoietic SCT. Bone Marrow Transplant. 2010;45(12):1710–8.

    Article  PubMed  CAS  Google Scholar 

  53. Shimoni A, Hardan I, Shem-Tov N, Yeshurun M, Yerushalmi R, Avigdor A, et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia. 2006;20(2):322–8.

    Article  PubMed  CAS  Google Scholar 

  54. Magenau J, Tobai H, Pawarode A, Braun T, Peres E, Reddy P, et al. Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies. Blood. 2011;118(15):4258–64.

    Article  PubMed  CAS  Google Scholar 

  55. Chevallier P, Labopin M, Buchholz S, Ganser A, Ciceri F, Lioure B, et al. Clofarabine-containing conditioning regimen for allo-SCT in AML/ALL patients: a survey from the Acute Leukemia Working Party of EBMT. Eur J Haematol. 2012;89(3):214–9.

    Article  PubMed  CAS  Google Scholar 

  56. Schmid C, Labopin M, Nagler A, Niederwieser D, Castagna L, Tabrizi R, et al. Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. 2012;119(6):1599–606.

  57. Collins Jr RH, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15(2):433–44.

    PubMed  Google Scholar 

  58. Warlick ED, DeFor T, Blazar BR, Burns L, Verneris MR, Ustun C, et al. Successful remission rates and survival after lymphodepleting chemotherapy and donor lymphocyte infusion for relapsed hematologic malignancies postallogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012;18(3):480–6.

    Article  PubMed  Google Scholar 

  59. Schroeder T, Czibere A, Platzbecker U, Bug G, Uharek L, Luft T, et al. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Leukemia. 2013;27(6):1229–35.

    Article  PubMed  CAS  Google Scholar 

  60. de Lima M, Giralt S, Thall PF, de Padua Silva L, Jones RB, Komanduri K, et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer. 2010;116(23):5420–31.

    Article  PubMed  Google Scholar 

  61. Choi J, Ritchey J, Prior JL, Holt M, Shannon WD, Deych E, et al. In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. Blood. 2010;116(1):129–39.

    Article  PubMed  CAS  Google Scholar 

  62. • Goodyear OC, Dennis M, Jilani NY, Loke J, Siddique S, Ryan G, et al. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood. 2012;119(14):3361–9. Azacitidine is shown here to potentially enhance GVL effects by eliciting cytotoxic T-cell responses and attenuating GVHD by increasing the number of regulatory T cells.

    Article  PubMed  CAS  Google Scholar 

  63. Metzelder S, Wang Y, Wollmer E, Wanzel M, Teichler S, Chaturvedi A, et al. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood. 2009;113(26):6567–71.

    Article  PubMed  CAS  Google Scholar 

  64. Sharma M, Ravandi F, Bayraktar UD, Chiattone A, Bashir Q, Giralt S, et al. Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib. Biol Blood Marrow Transplant. 2011;17(12):1874–7.

    Article  PubMed  CAS  Google Scholar 

  65. • Metzelder SK, Schroeder T, Finck A, Scholl S, Fey M, Gotze K, et al. High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses. Leukemia. 2012;26(11):2353–9. This article describes the clinical activity of sorafenib in FLT3-ITD-positive AML, and this should be considered as a treatment of post-HSCT relapse in this cohort.

    Article  PubMed  CAS  Google Scholar 

Download references

Compliance with ethics Guidelines

Conflict of Interest

John Magenau and Daniel Ricardo Couriel declare that they have no conflict of interest

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, University of Michigan Comprehensive Cancer Center, 1500 E. Medical Center Dr., Med Inn; C409, Ann Arbor, MI, 48109-5948, USA

    John Magenau

  2. Adult Blood and Marrow Transplantation Program, Division of Hematology/Oncology, University of Michigan Comprehensive Cancer Center, 1500 E. Medical Center Dr., 7322 CC, Ann Arbor, MI, 48109-5948, USA

    Daniel R. Couriel

Authors
  1. John Magenau
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel R. Couriel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John Magenau.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Magenau, J., Couriel, D.R. Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia: To Whom, When, and How. Curr Oncol Rep 15, 436–444 (2013). https://doi.org/10.1007/s11912-013-0340-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-013-0340-6

Keywords

Search

Navigation